abt 491 has been researched along with Disease Models, Animal in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Collange, O; Garvey, LH; Geny, B; Mertes, PM; Nicoll, S; Oulehri, W; Tacquard, C; Tuzin, N | 1 |
| Atici, A; Bozlu, G; Nayci, A; Okuyaz, C; Polat, A; Taskinlar, H; Turhan, AH | 1 |
2 other study(ies) available for abt 491 and Disease Models, Animal
| Article | Year |
|---|---|
Treatment with a platelet-activating factor receptor antagonist improves hemodynamics and reduces epinephrine requirements, in a lethal rodent model of anaphylactic shock.
Topics: Anaphylaxis; Animals; Disease Models, Animal; Epinephrine; Hemodynamics; Imidazoles; Indoles; Platelet Membrane Glycoproteins; Rats; Receptors, G-Protein-Coupled | 2020 |
Platelet-activating factor antagonist (ABT-491) decreases neuronal apoptosis in neonatal rat model of hypoxic ischemic brain injury.
Topics: Analysis of Variance; Animals; Animals, Newborn; Apoptosis; Caspase 3; Cell Count; Disease Models, Animal; Drug Administration Schedule; Hypoxia-Ischemia, Brain; Imidazoles; In Situ Nick-End Labeling; Indoles; Platelet Activating Factor; Rats | 2007 |